Renal denervation is a minimally invasive catheter-based technique. It is a radiofrequency or ultrasound ablation technique used to treat uncontrolled hypertension. Renal denervation is a catheter-based endovascular treatment used to treat hypertension that is uncontrolled by medication. A catheter emits radiofrequency radiation across many electrodes throughout the process. A radiofrequency pulse is delivered to the renal artery, causing the arterial wall to ablate, lowering nerve activity and, as a result, blood pressure. The advancement of catheter-based interventional therapy has shown significant results in validating improved blood pressure control in patients with uncontrolled hypertension, vascular, and cardiovascular illnesses.
According to the International Journal of Hypertension in 2013, atrial hypertension affects about 24.8 percent of the worldwide population and is associated with morbidity and death. The growing incidence of hypertension combined with ineffective antihypertensive medications, the long-term effects of renal denervation, and the rapid development of renal denervation devices are projected to fuel the growth of the renal denervation devices market. With the FDA's approval of the Symplicity HTN-4 renal denervation device, the market is predicted to rise dramatically due to its tailored radiofrequency energy delivery, which reduces the potential hazard to neighboring tissues. The market for renal denervation devices and associated procedures is also driven by benefits such as increased safety, shorter treatment times, long-term effects, and the growing prevalence of uncontrolled & treatment-resistant hypertension.
Europe is predicted to have the largest market share due to high R&D expenditures made by industry competitors operating in the area.
Coherent Market Insights' regional segmentation of the worldwide renal denervation devices market includes North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The European market for renal denervation devices is thought to be the largest, owing to a rising number of drug-resistant hypertension cases and technical breakthroughs in the production of effective devices. According to the American Heart Association, over 33% (almost 70 million individuals) of the adult population in the United States suffer from excessive blood pressure in 2013. The rising prevalence of uncontrolled hypertension and increased FDA medication approvals are likely to be the primary drivers driving market expansion in North America during the forecast period.
Posts
0 Comments